A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 05 2020
Historique:
received: 06 10 2019
revised: 19 12 2019
accepted: 27 01 2020
pubmed: 31 1 2020
medline: 7 2 2021
entrez: 31 1 2020
Statut: ppublish

Résumé

Gastrointestinal cancers remain areas of high unmet need despite advances in targeted and immunotherapies. Here, we demonstrate potent, tumor-selective efficacy with PF-07062119, a T-cell engaging CD3 bispecific targeting tumors expressing Guanylyl Cyclase C (GUCY2C), which is expressed widely across colorectal cancer and other gastrointestinal malignancies. In addition, to address immune evasion mechanisms, we explore combinations with immune checkpoint blockade agents and with antiangiogenesis therapy. PF-07062119 activity was evaluated We demonstrate that GUCY2C-positive tumors can be targeted with an anti-GUCY2C/anti-CD3ε bispecific, with selective drug biodistribution to tumors. PF-07062119 showed potent T-cell-mediated These data highlight the potential for PF-07062119 to demonstrate efficacy and improve patient outcomes in colorectal cancer and other gastrointestinal malignancies.

Identifiants

pubmed: 31996389
pii: 1078-0432.CCR-19-3275
doi: 10.1158/1078-0432.CCR-19-3275
doi:

Substances chimiques

Antibodies, Bispecific 0
CD3 Complex 0
CD3E protein, human 0
GUCY2C protein, human EC 4.6.1.2
Receptors, Enterotoxin EC 4.6.1.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2188-2202

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Divya Mathur (D)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York. divya.mathur@pfizer.com puja.sapra@pfizer.com.

Adam R Root (AR)

Pfizer WorldWide R&D, Cambridge, Massachusetts.

Bozena Bugaj-Gaweda (B)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Stephanie Bisulco (S)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Xingzhi Tan (X)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Wei Fang (W)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Jessica C Kearney (JC)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Justin Lucas (J)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Magali Guffroy (M)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Jonathan Golas (J)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Cynthia M Rohde (CM)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Chad Stevens (C)

Pfizer WorldWide R&D, Andover, Massachusetts.

Cris Kamperschroer (C)

Pfizer WorldWide R&D, Groton, Connecticut.

Kerry Kelleher (K)

Pfizer WorldWide R&D, Cambridge, Massachusetts.

Rosemary F Lawrence-Henderson (RF)

Pfizer WorldWide R&D, Andover, Massachusetts.

Erik Upeslacis (E)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Johnny Yao (J)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Jatin Narula (J)

Pfizer WorldWide R&D, Cambridge, Massachusetts.

Edward R LaVallie (ER)

Pfizer WorldWide R&D, Cambridge, Massachusetts.

Diane R Fernandez (DR)

Pfizer WorldWide R&D, La Jolla, California.

Bernard S Buetow (BS)

Pfizer WorldWide R&D, La Jolla, California.

Edward Rosfjord (E)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Laird Bloom (L)

Pfizer WorldWide R&D, Cambridge, Massachusetts.

Lindsay E King (LE)

Pfizer WorldWide R&D, Andover, Massachusetts.

Lioudmila Tchistiakova (L)

Pfizer WorldWide R&D, Cambridge, Massachusetts.

Anhco Nguyen (A)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York.

Puja Sapra (P)

Pfizer WorldWide Research and Development (R&D), Pearl River, New York. divya.mathur@pfizer.com puja.sapra@pfizer.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH